Clinical Report: Analysis of Five Cases of POU2F3-Positive SmCC
Overview
Revise to specify the diagnostic significance of POU2F3 in relation to existing markers.
Background
Expand on the consequences of lacking neuroendocrine markers for treatment options and patient outcomes.
Data Highlights
Patient
Age
Sex
Tumor Location
Follow-up Outcome
1
67
Female
Bladder
Distant metastases
2
62
Female
Bladder
Distant metastases
3
69
Male
Ureter
Distant metastases
4
70
Male
Ureter
No metastases reported
5
70
Male
Renal pelvis
No metastases reported
Key Findings
All five cases exhibited diffuse POU2F3 expression.
Histological examination revealed small round blue cells with a high nuclear-to-cytoplasmic ratio.
Loss of conventional neuroendocrine markers (CgA and Syn) was noted in all cases.
Aberrant p53 expression was observed in all cases, with RB1 loss in four cases.
During follow-up, three patients developed distant metastases.
Clinical Implications
The identification of POU2F3 as a marker in urinary tract SmCC may improve diagnostic accuracy, particularly in cases lacking traditional neuroendocrine markers. Clinicians should consider incorporating POU2F3 testing in the evaluation of suspected SmCC to better characterize tumor phenotypes.
Conclusion
Highlight the importance of further research and potential clinical trials to confirm the utility of POU2F3.
